

PRELIMINARY AMENDMENT
Serial No.: 09/610,891

tumor-associated antigen stimulates a humoral response when exposed on a proliferation-incompetent cell in the presence of a cytokine.

24. The vaccine of claim 23, wherein said proliferation-incompetent cell is autologous.

25. The vaccine of claim 23 wherein said proliferation-incompetent cell is allogeneic.

A1
R-126 26
27. The vaccine of claim 23, wherein said cytokine is expressed by a second non-cancerous cell.

27
28. The vaccine of claim 23, wherein said cytokine is GM-CSF.

28
29. The vaccine of claim 23, wherein said proliferation-incompetent cell is a prostate cell.

29
30. The vaccine of claim 23, wherein said antigen has a molecular weight selected from the group consisting of 250 kD, 160 kD, 150 kD, 130 kD, 105 kD, 60 kD, 32 kD, 31 kD, 27 kD, 26 kD, 14 kD and 12 kD, as determined by SDS-PAGE, and wherein said antigen does not cross-react immunologically with prostate-specific antigen.

30
31. The vaccine of claim 23, comprising a host cell comprising said nucleic acid encoding a tumor-associated antigen, wherein said tumor-associated antigen is expressed at the surface of said host cell.